Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 16/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014681 | 0.90 | IGF1R (0.53) | IGF1RTNK2 | |
| SCHEMBL6014701 | 0.85 | BACE1 (0.40) | IGF1RTNK2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6014697 | 0.83 | IGF1R (0.38) | IGF1RTNK2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5415358 | 0.79 | IGF1R (0.50) | IGF1RTNK2 | |
| SCHEMBL6014743 | 0.79 | IGF1R (0.57) | IGF1RTNK2 | |
| SCHEMBL6014690 | 0.77 | IGF1R (0.49) | IGF1RTNK2 | |
| SCHEMBL2460528 | 0.76 | IGF1R (0.69) | IGF1RTNK2 | |
| SCHEMBL2459989 | 0.76 | IGF1R (0.69) | IGF1RTNK2 | |
| SCHEMBL2459988 | 0.76 | IGF1R (0.69) | IGF1RTNK2 | |
| SCHEMBL5114672 | 0.74 | IGF1R (0.57) | IGF1RTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-A2 | IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037836-A2 | IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |